News Sentiment

SPRY sentiment intelligence

ARS Pharmaceuticals, Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 45 Balanced news tone 29 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 7.94 Week of 10 Jul 2026
Weighted tone 45/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 20

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-7.2% over one week, -18.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction -7.2% Price reacting lower
Trend fit Trend inactive -18.6% over four weeks
Fair value -22.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 14
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 20
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 4
simplywall.st 4
ACCESS Newswire 3
PR Newswire 2
www.marketscreener.com 2
TradingView 2
GlobeNewswire 1

Event Lens

What the news is about

Classified themes
Market update 11
Earnings 11
Regulatory and legal 7

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-29 of 29
Stock Titan Direct company coverage

ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit

ARS Pharmaceuticals (NASDAQ: SPRY) has announced significant leadership changes effective July 15, 2026. Richard Lowenthal resigned from the Board of Directors to qualify for severance, and Chief Medical Officer Sarina Tanimoto, M.D., ceased employment due to a termination withou

Tone
Negative 38/100
Event
Market update
Published
17 Jul 2026 19:40
Source
Stock Titan
PR Newswire Direct company coverage

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Pomerantz LLP is investigating ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors following a significant stock price drop. The investigation concerns potential securities fraud or unlawful business practices after the company disclosed that its product, neffy® (epin

Tone
Negative 19/100
Event
Regulatory and legal
Published
16 Jul 2026 14:12
Source
PR Newswire
Stock Titan Direct company coverage

Millennium group discloses ARS Pharmaceuticals (SPRY) ownership below 5%

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 2 to a Schedule 13G regarding their beneficial ownership of ARS Pharmaceuticals, Inc. common stock. The filing indicates that Integ

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 22:09
Source
Stock Titan
ACCESS Newswire Direct company coverage

ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) following a significant drop in its share price. This investigation was prompted by the company's disclosure that its flagship product, Neffy®, did not receive ant

Tone
Negative 18/100
Event
Regulatory and legal
Published
08 Jul 2026 18:11
Source
ACCESS Newswire
GlobeNewswire Direct company coverage

ARS Pharmaceuticals Announces CEO Succession

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) has announced a CEO succession, with co-founder Richard Lowenthal transitioning out of his role. Donn Casale, previously President, has been appointed as the new CEO and Director, effective July 7, 2026. The company expressed gratitude for

Tone
Positive 65/100
Event
Market update
Published
08 Jul 2026 09:11
Source
GlobeNewswire
Investing.com Direct company coverage

ARS Pharmaceuticals names Donn Casale as new CEO

ARS Pharmaceuticals (NASDAQ:SPRY) has announced that co-founder and CEO Richard Lowenthal has stepped down, with Donn Casale appointed as the new CEO. Casale, formerly President, brings over 25 years of biopharmaceutical leadership experience, and is tasked with growing the neffy

Tone
Positive 64/100
Event
Market update
Published
07 Jul 2026 22:09
Source
Investing.com
Quiver Quantitative Direct company coverage

ARS Pharmaceuticals Appoints Donn Casale CEO, Succeeds Co-Founder Richard Lowenthal

ARS Pharmaceuticals, Inc. has announced a leadership transition, with co-founder Richard Lowenthal stepping down as CEO after over a decade to be succeeded by Donn Casale, effective July 7, 2026. Casale, previously the company's President, brings over 25 years of biopharmaceutica

Tone
Positive 74/100
Event
Market update
Published
07 Jul 2026 20:41
Source
Quiver Quantitative
Stock Titan Direct company coverage

ARS Pharmaceuticals taps Donn Casale as CEO after Lowenthal exit

ARS Pharmaceuticals (Nasdaq: SPRY) announced that co-founder and CEO Richard Lowenthal ceased serving as an employee and officer on July 6, 2026. Donn Casale, previously President, has been appointed CEO and Director effective July 7, 2026. Casale brings over 25 years of commerci

Tone
Negative 38/100
Event
Market update
Published
07 Jul 2026 20:29
Source
Stock Titan
www.marketscreener.com Direct company coverage

ARS Pharmaceuticals, Inc. Announces Appointment of Donn Casale as Director, Effective July 7, 2026

ARS Pharmaceuticals, Inc. announced the appointment of Donn Casale, currently President, as a Director, effective July 7, 2026. Casale brings over 25 years of biopharmaceutical experience, with a strong background in commercial leadership and scaling innovative products. His prev

Tone
Positive 71/100
Event
Market update
Published
07 Jul 2026 20:09
Source
www.marketscreener.com
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Is Investigating ARS Pharmaceuticals, Inc. (SPRY) And Encourages Stockholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against ARS Pharmaceuticals, Inc. (SPRY) following a significant stock drop. The investigation stems from the company's disclosure that its flagship product, Neffy®, received no new commercial formulary addition

Tone
Negative 29/100
Event
Regulatory and legal
Published
04 Jul 2026 07:40
Source
ACCESS Newswire
ACCESS Newswire Direct company coverage

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ARS Pharmaceuticals, Inc. (ARS) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ARS Pharmaceuticals, Inc. (ARS) following a sharp drop in its share price. This investigation stems from the disclosure that Neffy®, ARS's epinephrine nasal spray, received no new commercial formulary additions

Tone
Neutral 50/100
Event
Regulatory and legal
Published
01 Jul 2026 18:40
Source
ACCESS Newswire
PR Newswire Direct company coverage

ARS Pharmaceuticals Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of ARS Pharmaceuticals (SPRY)

Levi & Korsinsky, LLP has initiated an investigation into ARS Pharmaceuticals (NASDAQ: SPRY) following a significant drop in its stock price. The investigation stems from the company's disclosure that its flagship product, Neffy®, failed to secure new commercial formulary additio

Tone
Negative 13/100
Event
Regulatory and legal
Published
29 Jun 2026 17:40
Source
PR Newswire
www.marketscreener.com Direct company coverage

ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) dropped from Russell 2000 Growth-Defensive Index

ARS Pharmaceuticals, Inc. (NasdaqGM:SPRY) has been removed from the Russell 2000 Growth-Defensive Index. The company is a biopharmaceutical firm focused on treatments for allergic reactions and is commercializing neffy, an epinephrine nasal spray approved in several regions for e

Tone
Negative 38/100
Event
Market update
Published
29 Jun 2026 06:38
Source
www.marketscreener.com
Business Wire Direct company coverage

SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm has launched an investigation into ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) following a significant drop in its stock price. This investigation focuses on potential securities law violations after the company's flagship product, Neffy, failed to secure new for

Tone
Negative 10/100
Event
Regulatory and legal
Published
28 Jun 2026 16:10
Source
Business Wire
TradingView Direct company coverage

Price to earnings forward of ARS Pharmaceuticals, Inc. – NASDAQ:SPRY

This article provides a financial data point for ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), specifically its price-to-earnings forward ratio. It notes that the market is closed and there are no trades, and the information is presented without specific values. The page primarily co

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 05:40
Source
TradingView